<DOC>
	<DOCNO>NCT01601236</DOCNO>
	<brief_summary>This Phase 2A study adaptive design pilot study investigate efficacy safety daily Acthar administration diabetic patient nephropathy proteinuria . Patients type 1 diabetes mellitus ( T1DM ) T2DM currently take insulin enrol randomize 6 study group treat either Acthar Placebo 36 week , follow 4 week dose taper , 12 week observation period . The study compare three dose regimen Acthar ( 8 U [ 0.1 mL ] , 16 U [ 0.2 mL ] , 32 U [ 0.4 mL ] ) equivalent volume Placebo ensure double-blind nature study . Insulin-requiring patient enrol aid compliance daily SC administration study medication allow ease blood glucose control adjustment current insulin therapy event glycemic excursion . Routine safety measure , include glycemic control , monitor throughout study . The adaptive design component study allow re-assignment high dose group mid dose group unacceptable toxicity note per study protocol high dose group . Efficacy assess monitor serum creatinine , calculate eGFR , proteinuria ( via urinary protein creatinine ratio [ PCR ] ) . Serum cortisol concentration additional biomarkers blood urine also monitor .</brief_summary>
	<brief_title>Acthar Treatment Proteinuria Diabetic Nephropathy Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>Inclusion Criteria ( number 2 , 3 , 4 , 5 , 6 , 7 per protocol ) : Body mass index ≤ 45 kg/m2 screening . Diagnosis T1DM T2DM , HbA1c ≤ 9.0 % Visit 1A . Diagnosis T2DM make &gt; 30 year age ( diabetes develop young age , Cpeptide level may obtain confirmed diagnosis ) . Currently insulinrequiring Patients oral hypoglycemic therapy plus insulin eligible provided oral hypoglycemic agent ( ) administer dose regimen ( ) oral hypoglycemic therapy stable ≥ 12 week prior screen . No change oral hypoglycemic therapy plan anticipated treatment period . Renal Target Disease Requirements : The average two eGFR value collect screening ( Visits 1 1A ) must 2060 mL/min/1.73m2 ( calculate use abbreviated Modification Diet Renal Disease [ MDRD ] equation AND Protein creatinine ratio ( PCR ) ≥ 3.0 g/g OR total urine protein ≥ 3.0 g 24hour urine collection return Visit 1A . Antihypertensive Therapy : Treatment ACEI and/or ARB least 6 week prior screen Visit 1A , stable maintenance dose ≥ 14 day prior screen Visit 1A . No change ACEI ARB therapy plan anticipated period study . If treat additional antihypertensive therapy ( y ) , duration therapy ≥ 30 day prior screen Visit 1A , stable maintenance dose ≥ 14 day prior screen Visit 1A . If patient document intolerance ACEI and/or ARB therapy ( e.g . angioedema , hyperkalemia ) , may eligible study entry , Medical Monitor must consult case prior randomization . Mean systolic blood pressure ≤ 140 mmHg diastolic blood pressure ≤ 90 mmHg ≥ 3 seated reading take least 5 minute apart screen period Visit 1A . Exclusion Criteria ( number 2 , 3 , 4 , 5 , 7 , 11 per protocol ) : Therapies and/or Medications : History prior sensitivity Acthar porcine protein product . Chronic systemic corticosteroid use , define ≥ 20 mg prednisone equivalent systemic corticosteroid take 4 consecutive week within 6 month prior randomization . Topical , inhale , intraarticular corticosteroid allow . Planned treatment live live attenuate vaccine enrol study . Previous treatment drug investigate treatment diabetic nephropathy within 6 month prior randomization . Contraindication Acthar per Prescribing Information Section 4 : scleroderma , osteoporosis , systemic fungal infection , ocular herpes simplex , recent surgery , history presence peptic ulcer , congestive heart failure , uncontrolled hypertension , primary adrenocortical insufficiency , adrenal cortical hyperfunction . For purpose study , history peptic ulcer define ≤ 6 month prior Visit 1A . Diabetes Target Disease Exceptions : Severely uncontrolled diabetes mellitus judge Principal Investigator HbA1c &gt; 9 % screen Visit 1A . Fasting serum glucose &gt; 230 mg/dL BOTH screen Visits 1 1A . History diabetic ketoacidosis nonketotic hyperosmolar coma within 6 month screen . History ocular laser photocoagulation therapy within 6 month screen OR diabetic retinopathy , diabetic macular edema , cataract associate impairment visual acuity affect adherence dose administration SC injection . Patients unwilling titrate insulin blood glucose control adjustment hypoglycemic therapy require study . Renal Target Disease Exceptions : History clinical renal biopsy evidence nondiabetic renal disease Patients require diagnostic interventional procedure require intravenous contrast agent must delay screening/randomization least 14 day Tuberculosis : Any patient positive Interferongamma release assay , OR sign symptom concern active tuberculosis . Cardiovascular : History congestive heart failure ( NYHA Functional Class IIIIV ) . History dilate cardiomyopathy ejection fraction &lt; 40 % . 1 . Exceptions require approval Medical Monitor . Patient follow within 3 month screen : 1 . Unstable angina 2 . Myocardial infarction 3 . Coronary artery bypass graft percutaneous transluminal coronary angioplasty 4 . Transient ischemic attack cerebrovascular accident 5 . Unstable arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>H.P . Acthar Gel</keyword>
	<keyword>Acthar</keyword>
	<keyword>diabetic nephropathy</keyword>
	<keyword>proteinuria</keyword>
	<keyword>nephrotic syndrome</keyword>
</DOC>